Pancreatic NeoplasmsERPANDIS-MRVNCT04317352
Multivisceral Resection in Distal Pancreatectomy
An observational study of Pancreatic Neoplasms and Surgical Procedure, Unspecified, run by Universidad de Extremadura at 1 site in Spain.
Trial summary
The objective of the study is to evaluate the characteristics of the patients and the results of morbidity and mortality after distal pancreatectomy isolated or accompanied by multivisceral resection including cholecystectomy. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Neoplasms, Surgical Procedure, Unspecified
- What is being tested?
- MVR
- Type of treatment
- Surgery or procedure
- How many people
- 435 participants
- Where
- 1 siteSpain
- Study dates
- 1 Mar 2019to 1 Mar 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: Patients undergoing distal pancreatectomy for primary pancreatic tumor at participating centers during the period from January 2009 to December 2018
Who may be able to join
- Any distal pancreatectomy (DP) with multivisceral resection (MVR) defining MVR as any organ different from distal pancreas or spleen
Who cannot join
- Distal Pancreatectomy with celiac trunk resection (Appleby procedure) or portal vein resection.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Distal Pancreatectomy With Multivisceral Resection: A Multicentric Study
The objective of the study is to evaluate the characteristics of the patients and the results of morbidity and mortality after distal pancreatectomy isolated or accompanied by multivisceral resection including cholecystectomy.
Read the detailed description
Multicenter study that includes patients operated on for distal pancreatectomy between January 2009 to December 2019 for primary pancreatic tumors. Both open or laparoscopic approaches are considered in the study. The objective is to evaluate the characteristics of the patients and the results of morbidity and mortality after distal pancreatectomy isolated or accompanied by multivisceral resection including cholecystectomy. For this, demographic data, variables related to the tumor, surgical intervention and postoperative evolution were collected.
Definitions:
Diagnosis was based mainly on computed tomography (CT scan), Magnetic Resonance (MRI) and endoscopic ultrasonography (USE) plus biopsy. Surgical technique includes open and laparoscopic approach with or without spleen preservation. Complications were assessed at 90 days using the Clavien - Dindo classification, and those defined as Clavien - Dindo grade IIIA or higher were considered major. For the recording of complications, the medical and nursing notes of the electronic or histories of each patient were consulted. For the specific complications of pancreatic surgery, the definitions of the International Study Group on Pancreatic Surgery (ISGPS) of delayed gastric emptying (21), post-pancreatic hemorrhage (22) and pancreatic fistula were used. The resection margins of the surgical specimen were categorized according to the definitions of the Royal College of Pathologists: R0 (margin to the tumor ≥ 1mm), R1 (margin to the tumor <1mm) and R2 (macroscopically positive margin) (24). Tumors were staged according to the TNM classification 8 º Ed. (TNM). Follow up scheme was: 6-month outpatient clinic visit during first five years including tumoral markers and CT/MRI. After five years only once a year visit policy was applied.
Variables The following variables were studied: Epidemiological: age, sex, past medical history, medication, Charlson Index and American Society of Anesthesiology (ASA) classification; Clinical: symptoms due to mucinous neoplasm (MCN); Serological tests: leukocytes, amylase; hemoglobin (gr/dl), bilirubin, creatinin, prothrombin time, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9; Radiological/diagnostic: diagnostic tests performed (CT/MRI/EUS), number, size and location of MCN, vascular infiltration (arterial and venous) and preoperative biopsy; Surgical: type of approach (open/laparoscopy/conversion), spleen preservation, associated procedures (organs resected), type of closure of pancreatic remnant, intraoperative bleeding (ml); postoperative course: morbidity and mortality (according to the Clavien-Dindo (CD) classification) (13), pancreatic fistula, postoperative hemorrhage and delayed gastric empting, if present, was classified according to the International Group Study Pancreatic Surgery (IGSPS) classification (14,15), hospital stay and readmissions. The histological data retrieved were TNM: tumor size and lymph nodes harvested and R status. Postoperative follow-up (months) including endocrine and exocrine insufficiency rate.
- Being tested
- MVR
- Keywords
- Complications, distal pancreatectomy, Multivisceral, resection
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MVRProcedure or surgery
Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed.
| Study group | Role | What they receive |
|---|---|---|
| Multivisceral resection (MRV) | MVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed. Receives: Procedure: MVR |
What is being measured
The primary outcome is the main question the study is designed to answer.
Morbidity
Any complication in the postoperative period
Measured: 90 days
Mortality
If the patient dies in the postoperative period
Measured: 90 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2020
- Study start1 Mar 2019
- Primary completion31 Dec 2019
- Study completion1 Mar 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Pancreatic NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 435 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad de Extremadura
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gerardo Blanco-Fernández, Universidad de Extremadura
- Investigators
- José Manuel Ramia, MD, PhD, Study director, University of Guadalajara
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04317352
- Sponsor's protocol ID
- UE-CHU 003-2020
- Acronym
- ERPANDIS-MRV
- Status last verified
- Mar 2020
- First submitted
- 19 Mar 2020
- Last updated
- 23 Mar 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The study data will be available upon request to the principal investigator via e-mail.
Publications
Malinka T, Klein F, Andreou A, Pratschke J, Bahra M. Distal Pancreatectomy Combined with Multivisceral Resection Is Associated with Postoperative Complication Rates and Survival Comparable to Those After Standard Procedures. J Gastrointest Surg. 2018 Sep;22(9):1549-1556. doi: 10.1007/s11605-018-3804-z. Epub 2018 May 10.
PubMed 29748738Burdelski CM, Reeh M, Bogoevski D, Gebauer F, Tachezy M, Vashist YK, Cataldegirmen G, Yekebas E, Izbicki JR, Bockhorn M. Multivisceral resections in pancreatic cancer: identification of risk factors. World J Surg. 2011 Dec;35(12):2756-63. doi: 10.1007/s00268-011-1263-8.
PubMed 21938586Panzeri F, Marchegiani G, Malleo G, Malpaga A, Maggino L, Marchese T, Salvia R, Bassi C, Butturini G. Distal pancreatectomy associated with multivisceral resection: results from a single centre experience. Langenbecks Arch Surg. 2017 May;402(3):457-464. doi: 10.1007/s00423-016-1514-0. Epub 2016 Oct 27.
PubMed 27787606Irani JL, Ashley SW, Brooks DC, Osteen RT, Raut CP, Russell S, Swanson RS, Whang EE, Zinner MJ, Clancy TE. Distal pancreatectomy is not associated with increased perioperative morbidity when performed as part of a multivisceral resection. J Gastrointest Surg. 2008 Dec;12(12):2177-82. doi: 10.1007/s11605-008-0605-9. Epub 2008 Aug 2.
PubMed 18677539Song KB, Kwon J, Kim YW, Hwang DW, Lee JH, Hong S, Lee JW, Hwang K, Yoo D, Kim SC. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy. J Hepatobiliary Pancreat Sci. 2019 Jun;26(6):227-234. doi: 10.1002/jhbp.627. Epub 2019 May 11.
PubMed 30980486Nikfarjam M, Sehmbey M, Kimchi ET, Gusani NJ, Shereef S, Avella DM, Staveley-O'Carroll KF. Additional organ resection combined with pancreaticoduodenectomy does not increase postoperative morbidity and mortality. J Gastrointest Surg. 2009 May;13(5):915-21. doi: 10.1007/s11605-009-0801-2. Epub 2009 Feb 7.
PubMed 19198960Ramia JM, Del Rio-Martin JV, Blanco-Fernandez G, Cantalejo-Diaz M, Rotellar-Sastre F, Sabater-Orti L, Carabias-Hernandez A, Manuel-Vazquez A, Hernandez-Rivera PJ, Jaen-Torrejimeno I, Kalviainen-Mejia HK, Esteban-Gordillo S, Munoz-Forner E, De la Plaza R, Longoria-Dubocq T, De Armas-Conde N, Pardo-Sanchez F, Garces-Albir M, Serradilla-Martin M. Distal pancreatectomy with multivisceral resection: A retrospective multicenter study - Case series. Int J Surg. 2020 Oct;82:123-129. doi: 10.1016/j.ijsu.2020.08.024. Epub 2020 Aug 26.
PubMed 32860956
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Distal Pancreatectomy With Multivisceral Resection: A Multicentric Study
- ClinicalTrials.gov ID
- NCT04317352
- Acronym / sponsor ID
- ERPANDIS-MRV / UE-CHU 003-2020
- Keywords
- Complications, distal pancreatectomy, Multivisceral, resection
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 435 participants (actual)
- Lead sponsor
- Universidad de ExtremaduraUniversity, hospital or other
- Study start
- 1 Mar 2019 (actual)
- Primary completion
- 31 Dec 2019 (actual)
- Study completion
- 1 Mar 2020 (actual)
- First posted
- 23 Mar 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to evaluate the characteristics of the patients and the results of morbidity and mortality after distal pancreatectomy isolated or accompanied by multivisceral resection including cholecystectomy.
Detailed description
Multicenter study that includes patients operated on for distal pancreatectomy between January 2009 to December 2019 for primary pancreatic tumors. Both open or laparoscopic approaches are considered in the study. The objective is to evaluate the characteristics of the patients and the results of morbidity and mortality after distal pancreatectomy isolated or accompanied by multivisceral resection including cholecystectomy. For this, demographic data, variables related to the tumor, surgical intervention and postoperative evolution were collected.
Definitions:
Diagnosis was based mainly on computed tomography (CT scan), Magnetic Resonance (MRI) and endoscopic ultrasonography (USE) plus biopsy. Surgical technique includes open and laparoscopic approach with or without spleen preservation. Complications were assessed at 90 days using the Clavien - Dindo classification, and those defined as Clavien - Dindo grade IIIA or higher were considered major. For the recording of complications, the medical and nursing notes of the electronic or histories of each patient were consulted. For the specific complications of pancreatic surgery, the definitions of the International Study Group on Pancreatic Surgery (ISGPS) of delayed gastric emptying (21), post-pancreatic hemorrhage (22) and pancreatic fistula were used. The resection margins of the surgical specimen were categorized according to the definitions of the Royal College of Pathologists: R0 (margin to the tumor ≥ 1mm), R1 (margin to the tumor <1mm) and R2 (macroscopically positive margin) (24). Tumors were staged according to the TNM classification 8 º Ed. (TNM). Follow up scheme was: 6-month outpatient clinic visit during first five years including tumoral markers and CT/MRI. After five years only once a year visit policy was applied.
Variables The following variables were studied: Epidemiological: age, sex, past medical history, medication, Charlson Index and American Society of Anesthesiology (ASA) classification; Clinical: symptoms due to mucinous neoplasm (MCN); Serological tests: leukocytes, amylase; hemoglobin (gr/dl), bilirubin, creatinin, prothrombin time, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9; Radiological/diagnostic: diagnostic tests performed (CT/MRI/EUS), number, size and location of MCN, vascular infiltration (arterial and venous) and preoperative biopsy; Surgical: type of approach (open/laparoscopy/conversion), spleen preservation, associated procedures (organs resected), type of closure of pancreatic remnant, intraoperative bleeding (ml); postoperative course: morbidity and mortality (according to the Clavien-Dindo (CD) classification) (13), pancreatic fistula, postoperative hemorrhage and delayed gastric empting, if present, was classified according to the International Group Study Pancreatic Surgery (IGSPS) classification (14,15), hospital stay and readmissions. The histological data retrieved were TNM: tumor size and lymph nodes harvested and R status. Postoperative follow-up (months) including endocrine and exocrine insufficiency rate.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Multivisceral resection (MRV) | – | Procedure: MVRMVR: Multivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients undergoing distal pancreatectomy for primary pancreatic tumor at participating centers during the period from January 2009 to December 2018
Key inclusion criteria (1 listed)
- Any distal pancreatectomy (DP) with multivisceral resection (MVR) defining MVR as any organ different from distal pancreas or spleen
Key exclusion criteria (1 listed)
- Distal Pancreatectomy with celiac trunk resection (Appleby procedure) or portal vein resection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MVRMultivisceral resection was considered when the exeresis of an organ other than the pancreatic body-tail and / or spleen was performed. | Procedure or surgery | Multivisceral resection (MRV) |
Primary outcome
Morbidity
Time frame: 90 days
Any complication in the postoperative period
Mortality
Time frame: 90 days
If the patient dies in the postoperative period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2020.
- Background: PubMed 29748738Malinka T, Klein F, Andreou A, Pratschke J, Bahra M. Distal Pancreatectomy Combined with Multivisceral Resection Is Associated with Postoperative Complication Rates and Survival Comparable to Those After Standard Procedures. J Gastrointest Surg. 2018 Sep;22(9):1549-1556. doi: 10.1007/s11605-018-3804-z. Epub 2018 May 10.
- Background: PubMed 21938586Burdelski CM, Reeh M, Bogoevski D, Gebauer F, Tachezy M, Vashist YK, Cataldegirmen G, Yekebas E, Izbicki JR, Bockhorn M. Multivisceral resections in pancreatic cancer: identification of risk factors. World J Surg. 2011 Dec;35(12):2756-63. doi: 10.1007/s00268-011-1263-8.
- Background: PubMed 27787606Panzeri F, Marchegiani G, Malleo G, Malpaga A, Maggino L, Marchese T, Salvia R, Bassi C, Butturini G. Distal pancreatectomy associated with multivisceral resection: results from a single centre experience. Langenbecks Arch Surg. 2017 May;402(3):457-464. doi: 10.1007/s00423-016-1514-0. Epub 2016 Oct 27.
- Background: PubMed 18677539Irani JL, Ashley SW, Brooks DC, Osteen RT, Raut CP, Russell S, Swanson RS, Whang EE, Zinner MJ, Clancy TE. Distal pancreatectomy is not associated with increased perioperative morbidity when performed as part of a multivisceral resection. J Gastrointest Surg. 2008 Dec;12(12):2177-82. doi: 10.1007/s11605-008-0605-9. Epub 2008 Aug 2.
- Background: PubMed 30980486Song KB, Kwon J, Kim YW, Hwang DW, Lee JH, Hong S, Lee JW, Hwang K, Yoo D, Kim SC. Prognostic value of adjacent organ resection in patients with left-sided pancreatic ductal adenocarcinoma following distal pancreatectomy. J Hepatobiliary Pancreat Sci. 2019 Jun;26(6):227-234. doi: 10.1002/jhbp.627. Epub 2019 May 11.
- Background: PubMed 19198960Nikfarjam M, Sehmbey M, Kimchi ET, Gusani NJ, Shereef S, Avella DM, Staveley-O'Carroll KF. Additional organ resection combined with pancreaticoduodenectomy does not increase postoperative morbidity and mortality. J Gastrointest Surg. 2009 May;13(5):915-21. doi: 10.1007/s11605-009-0801-2. Epub 2009 Feb 7.
- Derived from this study: PubMed 32860956Ramia JM, Del Rio-Martin JV, Blanco-Fernandez G, Cantalejo-Diaz M, Rotellar-Sastre F, Sabater-Orti L, Carabias-Hernandez A, Manuel-Vazquez A, Hernandez-Rivera PJ, Jaen-Torrejimeno I, Kalviainen-Mejia HK, Esteban-Gordillo S, Munoz-Forner E, De la Plaza R, Longoria-Dubocq T, De Armas-Conde N, Pardo-Sanchez F, Garces-Albir M, Serradilla-Martin M. Distal pancreatectomy with multivisceral resection: A retrospective multicenter study - Case series. Int J Surg. 2020 Oct;82:123-129. doi: 10.1016/j.ijsu.2020.08.024. Epub 2020 Aug 26.
- Individual participant dataSharing planned: Undecided. The study data will be available upon request to the principal investigator via e-mail.
Related trials for Pancreatic Neoplasms
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer
RecruitingPhase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
RecruitingPhase 1/2
Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors
Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Active, not recruitingPhase 2
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Pancreatic Cancer, Circulating Tumor Cell
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
José Manuel Ramia, MD, PhD study director
University of Guadalajara
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Neoplasms and Surgical Procedure, Unspecified, run by Universidad de Extremadura at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Morbidity (time frame: 90 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04317352, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2020.